Current status of potential therapeutic candidates for the COVID-19 crisis

IF 8.8 2区 医学 Q1 IMMUNOLOGY Brain, Behavior, and Immunity Pub Date : 2020-07-01 DOI:10.1016/j.bbi.2020.04.046
Jiancheng Zhang , Bing Xie , Kenji Hashimoto
{"title":"Current status of potential therapeutic candidates for the COVID-19 crisis","authors":"Jiancheng Zhang ,&nbsp;Bing Xie ,&nbsp;Kenji Hashimoto","doi":"10.1016/j.bbi.2020.04.046","DOIUrl":null,"url":null,"abstract":"<div><p>As of April 15, 2020, the ongoing coronavirus disease 2019 (COVID-2019) pandemic has swept through 213 countries and infected more than 1,870,000 individuals, posing an unprecedented threat to international health and the economy. There is currently no specific treatment available for patients with COVID-19 infection. The lessons learned from past management of respiratory viral infections have provided insights into treating COVID-19. Numerous potential therapies, including supportive intervention, immunomodulatory agents, antiviral therapy, and convalescent plasma transfusion, have been tentatively applied in clinical settings. A number of these therapies have provided substantially curative benefits in treating patients with COVID-19 infection. Furthermore, intensive research and clinical trials are underway to assess the efficacy of existing drugs and identify potential therapeutic targets to develop new drugs for treating COVID-19. Herein, we summarize the current potential therapeutic approaches for diseases related to COVID-19 infection and introduce their mechanisms of action, safety, and effectiveness.</p></div>","PeriodicalId":9199,"journal":{"name":"Brain, Behavior, and Immunity","volume":"87 ","pages":"Pages 59-73"},"PeriodicalIF":8.8000,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbi.2020.04.046","citationCount":"231","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain, Behavior, and Immunity","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0889159120305894","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 231

Abstract

As of April 15, 2020, the ongoing coronavirus disease 2019 (COVID-2019) pandemic has swept through 213 countries and infected more than 1,870,000 individuals, posing an unprecedented threat to international health and the economy. There is currently no specific treatment available for patients with COVID-19 infection. The lessons learned from past management of respiratory viral infections have provided insights into treating COVID-19. Numerous potential therapies, including supportive intervention, immunomodulatory agents, antiviral therapy, and convalescent plasma transfusion, have been tentatively applied in clinical settings. A number of these therapies have provided substantially curative benefits in treating patients with COVID-19 infection. Furthermore, intensive research and clinical trials are underway to assess the efficacy of existing drugs and identify potential therapeutic targets to develop new drugs for treating COVID-19. Herein, we summarize the current potential therapeutic approaches for diseases related to COVID-19 infection and introduce their mechanisms of action, safety, and effectiveness.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19危机潜在候选治疗方案的现状。
截至2020年4月15日,正在进行的2019冠状病毒病(COVID-2019)大流行已席卷213个国家,感染人数超过187万人,对国际卫生和经济构成前所未有的威胁。目前还没有针对COVID-19感染患者的特异性治疗方法。从过去呼吸道病毒感染管理中吸取的经验教训为治疗COVID-19提供了见解。许多潜在的治疗方法,包括支持性干预、免疫调节剂、抗病毒治疗和恢复期血浆输注,已初步应用于临床。其中一些疗法在治疗COVID-19感染患者方面提供了实质性的疗效。此外,正在进行密集的研究和临床试验,以评估现有药物的疗效,并确定潜在的治疗靶点,以开发治疗COVID-19的新药。在此,我们总结了目前与COVID-19感染相关疾病的潜在治疗方法,并介绍了它们的作用机制、安全性和有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
相关文献
Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation
IF 12.8 1区 医学American Journal of HematologyPub Date : 2013-02-05 DOI: 10.1002/ajh.23402
Aimee E. Hammerstrom, Joshua Howell, Alison Gulbis, Gabriela Rondon, Richard E. Champlin, Uday Popat
[Clinical Analysis of Reversible Posterior Encephalopathy Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation in Children].
IF 0 中国实验血液学杂志Pub Date : 2024-10-01 DOI: 10.19746/j.cnki.issn.1009-2137.2024.05.040
Zuo-Feng Li, Hao Xiong, Zhi Chen, Li Yang, Ming Sun, Wen-Jie Lu, Shan-Shan Qi, Fang Tao, Lin-Lin Luo, Yu-Qing Jiao
Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation
IF 6.5 2区 医学British Journal of HaematologyPub Date : 2003-06-20 DOI: 10.1046/j.1365-2141.2003.04447.x
Raymond Wong, Guillermo Z. Beguelin, Marcos De Lima, Sergio A. Giralt, Chitra Hosing, Cindy Ippoliti, Arthur D. Forman, Ashok J. Kumar, Richard Champlin, Daniel Couriel
来源期刊
CiteScore
29.60
自引率
2.00%
发文量
290
审稿时长
28 days
期刊介绍: Established in 1987, Brain, Behavior, and Immunity proudly serves as the official journal of the Psychoneuroimmunology Research Society (PNIRS). This pioneering journal is dedicated to publishing peer-reviewed basic, experimental, and clinical studies that explore the intricate interactions among behavioral, neural, endocrine, and immune systems in both humans and animals. As an international and interdisciplinary platform, Brain, Behavior, and Immunity focuses on original research spanning neuroscience, immunology, integrative physiology, behavioral biology, psychiatry, psychology, and clinical medicine. The journal is inclusive of research conducted at various levels, including molecular, cellular, social, and whole organism perspectives. With a commitment to efficiency, the journal facilitates online submission and review, ensuring timely publication of experimental results. Manuscripts typically undergo peer review and are returned to authors within 30 days of submission. It's worth noting that Brain, Behavior, and Immunity, published eight times a year, does not impose submission fees or page charges, fostering an open and accessible platform for scientific discourse.
期刊最新文献
Inhibition of TrkB-BDNF positive feedback loop attenuates intervertebral disc degeneration and low back pain in a composite mouse model. Activation of nuclear factor-kappa B in the nucleus accumbens core is necessary for chronic stress-induced glutamate and neuro-immune alterations that facilitate cocaine self-administration. Inflammation and psychomotor retardation in depression: The moderating role of glymphatic system L-tyrosine alleviates autism-like behavior in mice by remodeling the gut microbiota Neuropsychiatric sequelae in an experimental model of post-COVID syndrome in mice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1